A report from an expert panel published in PAIN® presents a consensus approach to assessing the clinical characteristics or phenotype of neuropathic pain. The consensus criteria, together with other research reporting recommendations, are intended to promote greater consistency and transparency in human studies of neuropathic pain. Information on genetic factors may help in understanding how neuropathic pain develops, leading to new approaches to treatment and prevention. The panel was convened by the International Association for the Study of Pain (IASP) and its Special Interest Group on Neuropathic Pain (NeuPSIG).
Neuropathic pain is a common and complex condition that can be caused by a wide range of diseases including diabetes, shingles, and trauma. It is characterized by shooting or burning pain, numbness, or exaggerated pain responses. To date, genetic studies have produced inconsistent results, due in part to variations in approaches used to identify and classify clinical expression of the condition. The panel sought to develop a set of “entry level” phenotype data to identify and classify patients with neuropathic pain, as well as appropriate comparison (control) groups.
To read about new therapeutic targets of neuropathic pain, click here.
To read about neuropathic pain reduction, click here.
Read a news story about the recommendations, with link to the journal article, here.